Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-06
2006-06-06
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S300000, C530S317000
Reexamination Certificate
active
07056883
ABSTRACT:
A therapeutic agent for soft tissue sarcoma (particularly synovial sarcoma), contains a histone deacetylase inhibitor (particularly a compound of formula I) as an active ingredient
REFERENCES:
patent: 4977138 (1990-12-01), Okuhara et al.
patent: 6403555 (2002-06-01), Skov
patent: 6905669 (2005-06-01), DiMartino
patent: 2002/0192727 (2002-12-01), Setaluri et al.
patent: 2004/0053820 (2004-03-01), Nakajima et al.
patent: 0 196 415 (1986-10-01), None
patent: 0 352 646 (1990-01-01), None
patent: 1 302 476 (2003-04-01), None
patent: 1426054 (2004-06-01), None
patent: 60149520 (1985-08-01), None
patent: WO 95/31977 (1995-11-01), None
patent: WO 98/39965 (1998-09-01), None
patent: WO 02/06307 (2002-01-01), None
patent: WO 02/085400 (2002-10-01), None
patent: WO 02/085883 (2002-10-01), None
patent: WO 03/015810 (2003-02-01), None
patent: WO 2003015810 (2003-02-01), None
patent: WO 03/088954 (2003-10-01), None
patent: WO 2004/075859 (2004-09-01), None
C Gorman, et al. The Hype and the Hope. Time (1998) 151(19). pp. 40-44. Included HTML copy referenced pp. 1-9.
T Gura. Systems for Identifying New Drugs are Often Faulty. Science (1997) 278 (Nov. 7), pp. 1041-1042.
GB Dermer. Another Anniversary for the War on Cancer. Bio/Technology (Mar. 12, 1994). p. 320.
R McKie. Cancer Research Set Back a Decade. The Observer Jun. 10, 2001. pp. 1-4 (HTML text).
J.M. Holand and E.Frei. Cancer Medicine, 5th Edition, Bast, et al. Ed. B.C. Decker Inc. Ontario. (2000). 24 pages.
K. Kusuzaki, et al. Photochem. Photobiol. (2005) preprint published Feb. 1, 2005. 16 pages.
R.R. Frey, et al. Bioorg. Med. Chem. Letters (2002), pp. 3443-3447.
A. Kawai, et al. Cancer Letters (2004), pp. 105-113.
M. Jung. Curr. Med. Chem. (2001), pp. 1505-1511.
G. Ranjgolikar, et al. Breast Cancer Res. Treat. (1998), pp. 29-38.
Y. Sasakawa, et al. Biochem. Pharm. (2003), pp. 897-906.
Y. Sasakawa, et al. Cancer Letters. (2003), pp. 161-168.
R. Furumai, et al. Cancer Res. (2002), pp. 4916-4921.
H.J. Kwon, et al. Int. J. Cancer (2002), pp. 290-296.
W.-G. Zhu and G.A. Otterson. Curr. Med. Chem. (2003), pp. 187-199.
M. Murata, et al. Jpn. J. Cancer. Res. (2000), pp. 1154-1160.
M.E. Goldsmith, et al. Clin. Cancer Res. (2003), pp. 5394-5401.
P.A. Voute, et al. Ann. Oncol. (1999), pp. 1211-1218.
M.H.M. Schwarzbach, et al. Int. J. Oncol. (2002), pp. 1211-1218.
W.K. Kelly, et al. “Histone deacetylase inhibitors: from target to clinical trials” Expert Opinion on Investigational Drugs.(2002) vol. 11, No. 12, pp. 1695-1713.
H. Nakajima, et al., Experimental Cell Research, vol. 241, pp. 126-133, “FR901228, A Potent Antitumor Antibiotic, is a Novel Histone Deacetylase Inhibitor”, 1998.
K. W. Li, et al., J. Am. Chem. Soc., vol. 118, No. 30, pp. 7237-7238, “Total Synthesis of the Antitumor Depsipeptide FR-901,228”, 1996.
H. Ueda, et al., The Journal of Antibiotics, vol. 47, No. 3, pp. 315-323, “FR901228, A Novel Antitumor Bicyclic Depsipeptide Produced by Chromobacterium Violaceum No. 968. III. Antitumor Activities on Experimental Tumors in Mice”, Mar. 1994.
H. Kosugi, et al., Jpn. J. Cancer. Res., vol. 92, pp. 529-536, “In Vivo Effects of a Histone Deacetylase Inhibitor, FK228, on Human Acute Promyelocytic Leukemia in NOD/SHI-SCID/SCID Mice”, May 2001.
R. L. Piekarz, et al., Blood, vol. 98, No. 9, pp. 2865-2868, “Inhibitor of Histone Deacetylation, Depsipeptide (FR901228), in the Treatment of Peripheral and Cutaneous T-Cell Lymphoma: A Case Report”, Nov. 2001.
Y. Sasakawa, et al., Biochemical Pharmacology, vol. 64, pp. 1079-1090, “Effects of FK228, A Novel Histone Deacetylase Inhibitor, on Human Lymphoma U-937 Cells In Vitro and In Vivo”, 2002.
M. S. Finnin, et al., NATURE, vol. 401, pp. 188-193, “Structures of a Histone Deacetylase Homologue Bound to the TSA and SAHA Inhibitors”, Sep. 9, 1999.
J. E. Eid, et al., Cell, vol. 102, pp. 839-848, “P300 Interacts with the Nuclear Proto-Oncoprotein SYT as Part of the Active Control of Cell Adhesion”, Sep. 15, 2000.
H. Kato, et al., The Journal of Biological Chemistry, vol. 277, No. 7, pp. 5498-5505. “SYT Associates with Human SNF/SWI Complexes and the C-Terminal Region of its Fusion Partner SSX1 Targets Histones”, Feb. 15, 2002.
C. Thaete, et al., Human Molecular Genetics, vol. 8, No. 4, pp. 585-591, “Functional Domains of the SYT and SYT-SSX Synovial Sarcoma Translocation Proteins and Co-Localization with the SNF Protein BRM in the Nucleus”, 1999.
Zhu, Wei-Guo and Otterson, Gregory A., “The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells,” Curr. Med. Chem.—Anti-Cancer Agenst, 2003, 3, pp. 187-199.
Michael Curtin, et al., “Histone Deacelytase Inhibitors: The Abbott Experience”, Current Medicinal Chemistry, vol. 10, No. 22, XP-008039441, 2003, pp. 2373-2392.
Martha C. Kutko, et al., Histone Deacetylase Inhibitors Induce Growth Suppression and Cell Death in Human Rhabdomyosarcoma in Vitro, Clinical Cancer Research, vol. 9, No. 15, XP-008039438, Nov. 15, 2003, pp. 5749-5755.
Jerry Jaboin, et al., “MS-27-275, an Inhibitor of Histone Deacetylase, Has Marked in Vitro and in Vivo Antitumor Activity Against Pediatric Solid Tumors”, Cancer Research, vol. 62, No. 21, XP-001202151, Nov. 1, 2002, pp. 6108-6115.
You Mie Lee, et al., “Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity” , Biochemical and Biophysical Research Communications, vol. 300, No. 1, XP-001202149, 2003, pp. 241-246.
Menachem Ailenberg, et al., “Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: Implications for use of TSA in Cancer therapy”, Biochemical and Biophysical Research Communications, vol 302, No. 2, XP-008039399, 2003, pp. 181-185.
Hirotsugu Ueda, et al., “FR901228, A Novel Antihumor Bicyclic Depsipeptide Produced by Chromabacterium violaceum No. 968”, The Journal of Antibiotics, vol. 47, No. 3, XP-002960289, Mar. 1994, pp. 315-323.
Ito Tatsuo
Ouchida Mamoru
Ozaki Toshifumi
Astellas Pharma Inc.
Campell Bruce R.
Kosar Andrew D.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Therapeutic agent for soft tissue sarcoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for soft tissue sarcoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for soft tissue sarcoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3678898